Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

17.12 +0.04 (+0.23%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed... 
Via Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
TEVA Stock Earnings: Teva Pharmaceutical Indus Misses EPS, Beats Revenue for Q1 2024
TEVA stock results show that Teva Pharmaceutical Indus missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
The company missed first-quarter earnings forecasts by 4 cents a share, but sales beat. 
Via Investor's Business Daily
Wall Street Poised For Muted Open On Mixed Earnings, With More Fed Speeches In Store: Analyst Sees S&P 500 Crossing Late-March High
U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more speeches by Federal Reserve officials. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Investor Sentiment Falls Further, Dow Gains For Fifth Session
Via Benzinga
Topics Stocks
Exposures US Equities
Uber, Lyft And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
Via Benzinga
Topics Stocks
Exposures US Equities
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report. 
Via Investor's Business Daily
Teva to Present at the 2024 Bank of America Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact." 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23
The Israel-Hamas War has only adversely affected the stock returns of 6 of the 15 small cap Israeli- domiciled companies listed on U.S. exchanges but, In total, their returns have exceeded those of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
From Teva Pharmaceutical Industries Limited
Via Business Wire
3 No-Brainer Stocks to Buy With $600 Right Now
A relatively modest amount of money can go a long way when it's put to work in top-tier businesses with abundant catalysts. 
Via The Motley Fool
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.